Calling consciousness an "entropic engine" points to something psychologically obvious: selfhood costs energy. Maintaining a stable "me" model across time, contexts, and internal contradictions ...

A new research paper reframes the simulation hypothesis, asking whether reality could be simulated and what science can test.

This article, presented in the backdrop of the debates on the state of political theory in India, argues that the terms of debate need to shift to include the question of method of doing political ...

The Arts Council of Princeton (ACP) has announced a three-person exhibition, “Divergent Forms,” featuring the work of artists ...

A steaming bowl of pho becomes the most vivid thing in your visual field – the clear amber broth, bright green herbs, ruby red sriracha swirls, and sunny yellow lime wedges appearing almost ...

Thanks to Einstein’s relativity, time flows differently on Mars than on Earth. NIST scientists have now nailed down the ...

This year artificial intelligence stopped being all about the future and roared into the present. Time announced exclusively on TODAY Dec. 11 that it has recognized AI’s seismic impact by naming the ...

Time magazine has chosen "Architects of AI" as its Person of the Year 2025. The magazine said it opted to recognize artificial intelligence's vast influence across society, from media to politics to ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...